Chemodex

Dienogest

Product Code:
 
CDX-D0793
Product Group:
 
Other Biochemicals
Supplier:
 
Chemodex
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
+4°C
1 / 1
Chemical Structure

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
CDX-D0793-M01010 mg£65.00
Quantity:
CDX-D0793-M05050 mg£230.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Alternate Names/Synonyms:
STS 557; BAY 86-5258; (17alpha)-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; 17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile, 17-cyanomethyl-17-hydroxy-estra-4,9-dien-3-one; Dienogestril; Endometrion
Appearance:
White to beige powder.
CAS:
65928-58-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H361
InChi:
InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1
InChiKey:
AZFLJNIPTRTECV-FUMNGEBKSA-N
Long Description:
Chemical. CAS: 65928-58-7. Formula: C20H25NO2. MW: 311.42. Synthetic. Dienogest is an agonist of the progesterone receptor (PR). It is an orally active synthetic progestogen with approximately 10% of the relative affinity of progesterone. However it shows very potent progestagenic effects in the endometrium with some antiandrogenic activity and without any androgenic, glucocorticoid or mineralocorticoid effects. It has been used alone or in combination as a contraceptive and to treat uterine fibroids. Dienogest inhibits ovulation primarily through peripheral action rather than by central action on gonadotrophin secretion. Unlike other progestogens, except in the case of its strong effects in the uterus, dienogest is said to lack antiestrogenic effects, and does not antagonize the beneficial effects of estradiol, for instance in the metabolic and vascular systems. Dienogest also showed some possible antiprogestogenic activity in one animal bioassay when administered before but not at the same time as progesterone. It has shown to have anti-inflammatory activity.
MDL:
MFCD00868356
Molecular Formula:
C20H25NO2
Molecular Weight:
311.42
Package Type:
Vial
Precautions:
P280
Product Description:
Dienogest is an agonist of the progesterone receptor (PR). It is an orally active synthetic progestogen with approximately 10% of the relative affinity of progesterone. However it shows very potent progestagenic effects in the endometrium with some antiandrogenic activity and without any androgenic, glucocorticoid or mineralocorticoid effects. It has been used alone or in combination as a contraceptive and to treat uterine fibroids. Dienogest inhibits ovulation primarily through peripheral action rather than by central action on gonadotrophin secretion. Unlike other progestogens, except in the case of its strong effects in the uterus, dienogest is said to lack antiestrogenic effects, and does not antagonize the beneficial effects of estradiol, for instance in the metabolic and vascular systems. Dienogest also showed some possible antiprogestogenic activity in one animal bioassay when administered before but not at the same time as progesterone. It has shown to have anti-inflammatory activity.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
O=C1CCC2=C3[C@@]([C@@](CC[C@@]4(O)CC#N)([H])[C@]4(C)CC3)([H])CCC2=C1
Solubility Chemicals:
Soluble in DMSO (5mg/mL clear, warming). Insoluble in water.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.

References

(1) M. Ottel & A. Kurischko; Contraception 21, 61 (1980) | (2) R.H. Foster & M.I. Wilde; Drugs 56, 825 (1998) (Review) | (3) P.L. McCormack; Drugs 70, 2073 (2010) (Review) | (4) X. Ruan, et al.; Maturitas 71, 337 (2012) (Review) | (5) G. Grandi; Inflamm. Res. 65, 183 (2016) (Review)